Cell4Pharma's ciPTEC platforms are now available for our customers. We provide licenses and services based on our unique and patented human renal model ciPTEC.
Cell4Pharma is continuously working to succeed in our ambition to reduce drug-induced kidney injury via innovative in vitro platforms. To reach our goals, we provide our cell lines to the pharmaceutical industry, CRO companies and academic researchers via license agreements. Our experts are open to discuss your requests. For all our products, we provide detailed protocols.
All cells were derived from a healthy donor with informed consent, without any history of any (renal) inherited pathology. Our ciPTEC is conditionally immortalized via genetic modifications (introduction of SV40tsA58 and hTERT), resulting in a proliferation temperature of 33ºC and maturation temperature of 37ºC. For details and licensing opportunities, please contact one of our experts.
At this stage, three cell lines are available.
Human conditionally immortalized proximal tubular epithelial cell line. Stably transfected by SV40T and hTERT, subcloned and well-characterized. Expressing proximal tubular markers alkaline phosphatase, di-peptidiyl peptidase IV and ZO-1. Maintained transport functionality for sodium-dependent phosphate reabsorption, megalin-cubilin receptor mediated endocytosis, organic cation transport (SLC22A2); p-glycoprotein (ABCB1), multidrug resistance protein 2/4 (MRP2/4), breast cancer resistance protein (ABCG2) and a range of metabolic enzymes. See our publications for details.
Based on ciPTEC 14.4, including expression and functional uptake via organic anion transporter 1 (SLC22A6)
Based on ciPTEC 14.4, including expression and functional uptake via organic anion transporter 3 (SLC22A8)
At this stage, this model is under development and expected to be available soon. If you like to receive an update, please contact us.